PDS Biotechnology Corporation (PDSB) financial statements (2021 and earlier)

Company profile

Business Address 303A COLLEGE ROAD EAST
PRINCETON, NJ 08540
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments123588106130
Cash and cash equivalents123588106130
Other undisclosed current assets21111
Total current assets:143689107131
Noncurrent Assets
Property, plant and equipment00333
Intangible assets, net (including goodwill)3    
Intangible assets, net (excluding goodwill)3    
Other noncurrent assets 0000
Other undisclosed noncurrent assets(3)    
Total noncurrent assets:01443
TOTAL ASSETS:143693111134
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities211076
Accounts payable10433
Accrued liabilities10534
Debt  3 2
Restructuring reserve06   
Total current liabilities:361379
Noncurrent Liabilities
Long-term debt and lease obligation  17153
Long-term debt, excluding current maturities  17153
Total noncurrent liabilities:  17153
Total liabilities:36302212
Stockholders' equity
Stockholders' equity attributable to parent12306289122
Common stock00000
Additional paid in capital41223214190185
Accumulated deficit(29)(193)(152)(101)(62)
Total stockholders' equity:12306289122
TOTAL LIABILITIES AND EQUITY:143693111134

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(21)(43)(52)(40)(26)
Operating loss:(21)(43)(52)(40)(26)
Nonoperating income141100
Investment income, nonoperating141100
Other nonoperating expense   (0) 
Interest and debt expense(0)(1)(2)(1)(1)
Other undisclosed loss from continuing operations before equity method investments, income taxes    (2)
Loss from continuing operations before income taxes:(7)(44)(53)(41)(29)
Income tax expense (benefit)(0)3321
Net loss:(8)(41)(51)(39)(28)
Other undisclosed net income attributable to parent1    
Net loss attributable to parent:(7)(41)(51)(39)(28)
Preferred stock dividends and other adjustments    (4)
Net loss available to common stockholders, diluted:(7)(41)(51)(39)(32)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(8)(41)(51)(39)(28)
Comprehensive loss:(8)(41)(51)(39)(28)
Other undisclosed comprehensive income, net of tax, attributable to parent1    
Comprehensive loss, net of tax, attributable to parent:(7)(41)(51)(39)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: